Compare Inovio Pharmaceuticals Inc (INO) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Li Auto Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Li Auto Inc trades at $11.4 (market cap $10.71B). The key difference: Li Auto Inc is far larger — about 95.5× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Li Auto Inc for 101 Days on average.
| INO | LI | |
|---|---|---|
Market Cap | $112.19M | $10.71B |
Volume | 3,201,278 | 1,781,143 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.65 | $23.61 |
52-Week Low | $0.66 | $10.69 |
Typical Hold Time | 43 Days | 101 Days |
Enterprise Value | $83.51M | $139.58M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
Li Auto (LI) trades at $10.99, near its 52-week low, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. Revenue declined to $112.31B in 2025, with a net income margin of 1%, while cash flow from operations turned negative. The company faces intense competition in China's EV market, though new model launches like the Li i9 aim to revive growth.
The stock presents a high-risk opportunity, with a consensus price target of $15.18 implying upside, but investors must weigh analyst caution (43.75% buy rating) against execution risks and ongoing cash burn. Near-term performance hinges on delivery recovery and margin improvement amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
